Posted by Clinical Lab Products | Mar 9, 2010 | Cancer, Miscellaneous |
DiagnoCure Inc announced that the clinical utility of the PROGENSA PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline’s REDUCE trial of dutasteride.
Read MorePosted by Clinical Lab Products | Mar 3, 2010 | Cancer, Miscellaneous |
Myriad Genetics Inc announces the launch of PROLARIS, a 46-gene prognostic test which quantitatively determines the risk of recurrence in patients who have undergone prostatectomy surgery.
Read MorePosted by Clinical Lab Products | Jul 6, 2009 | Cancer, Miscellaneous, Osteoporosis |
Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis.
Read MorePosted by Clinical Lab Products | Jun 2, 2009 | Cancer, Miscellaneous |
A new blood test used in combination with a conventional prostate-specific antigen (PSA) screening sharply increases the accuracy of prostate cancer diagnosis, and could eliminate tens of thousands of unneeded, painful, and costly prostate biopsies annually, according to a study led by researchers at Dana-Farber Cancer Institute.
Read MorePosted by Clinical Lab Products | Mar 20, 2009 | Cancer, Miscellaneous |
The prostate cancer screening tests that have become an annual ritual for many men dont appear to reduce deaths from the disease among those with a limited life expectancy, according to early results of a major US study involving 75,000 men.
Read More